Anti-TNF therapy: where have we got to in 2005?
The blockade of TNF has had significant impact on the therapy of a number of chronic autoimmune diseases. In this chapter we review the concepts leading up to this therapy in rheumatoid arthritis (RA), how it spreads into other autoimmune diseases, and how greater understanding of its use has led to...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|
| _version_ | 1797082054246006784 |
|---|---|
| author | Feldmann, M Brennan, F Foxwell, B Taylor, P Williams, R Maini, R |
| author_facet | Feldmann, M Brennan, F Foxwell, B Taylor, P Williams, R Maini, R |
| author_sort | Feldmann, M |
| collection | OXFORD |
| description | The blockade of TNF has had significant impact on the therapy of a number of chronic autoimmune diseases. In this chapter we review the concepts leading up to this therapy in rheumatoid arthritis (RA), how it spreads into other autoimmune diseases, and how greater understanding of its use has led to augmented therapeutic benefit. There are still many limitations, but the prospects for the future are intriguing. |
| first_indexed | 2024-03-07T01:22:46Z |
| format | Journal article |
| id | oxford-uuid:90ed24b2-3eae-4f08-9f20-9d98ac812e76 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:22:46Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:90ed24b2-3eae-4f08-9f20-9d98ac812e762022-03-26T23:15:00ZAnti-TNF therapy: where have we got to in 2005?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:90ed24b2-3eae-4f08-9f20-9d98ac812e76EnglishSymplectic Elements at Oxford2005Feldmann, MBrennan, FFoxwell, BTaylor, PWilliams, RMaini, RThe blockade of TNF has had significant impact on the therapy of a number of chronic autoimmune diseases. In this chapter we review the concepts leading up to this therapy in rheumatoid arthritis (RA), how it spreads into other autoimmune diseases, and how greater understanding of its use has led to augmented therapeutic benefit. There are still many limitations, but the prospects for the future are intriguing. |
| spellingShingle | Feldmann, M Brennan, F Foxwell, B Taylor, P Williams, R Maini, R Anti-TNF therapy: where have we got to in 2005? |
| title | Anti-TNF therapy: where have we got to in 2005? |
| title_full | Anti-TNF therapy: where have we got to in 2005? |
| title_fullStr | Anti-TNF therapy: where have we got to in 2005? |
| title_full_unstemmed | Anti-TNF therapy: where have we got to in 2005? |
| title_short | Anti-TNF therapy: where have we got to in 2005? |
| title_sort | anti tnf therapy where have we got to in 2005 |
| work_keys_str_mv | AT feldmannm antitnftherapywherehavewegottoin2005 AT brennanf antitnftherapywherehavewegottoin2005 AT foxwellb antitnftherapywherehavewegottoin2005 AT taylorp antitnftherapywherehavewegottoin2005 AT williamsr antitnftherapywherehavewegottoin2005 AT mainir antitnftherapywherehavewegottoin2005 |